May 20, 2022

Kate Yen, PhD

Kate Yen, PhD, is the Founder and CEO of Auron Therapeutics. Prior to founding Auron, she was a Director at Agios Pharmaceuticals, where she led the IDH translational research team that supported the preclinical and clinical development and approval of two IDH mutant inhibitors, IDHIFA®  and TIBSOVO. She led the proof of concept studies that…